Literature DB >> 25634237

IgE-mediated allergic reactions after the first administration of glatiramer acetate in patients with multiple sclerosis.

Mercè Corominas1, Idoia Postigo, Victoria Cardona, Ramon Lleonart, Lucía Romero-Pinel, Jorge Martinez.   

Abstract

BACKGROUND: Immediate adverse reactions to glatiramer acetate (GA), a drug used in the treatment of patients with multiple sclerosis (MS), have been poorly investigated. We studied 3 MS patients who presented adverse reactions following GA administration. Two of them experienced severe anaphylactic reactions after the first administration and the other an eyelid edema upon reintroduction 6 months after GA withdrawal.
METHODS: Skin prick tests (SPT) to GA and mannitol were performed on all 3 patients and in 10 atopic controls. Specific IgE (sIgE) levels to GA, myelin basic protein (MBP) and MBP fragments were assessed in all 3 patients, 6 MS patients treated with GA for more than 6 month and 10 healthy donors. Specific IgG (sIgG) to GA was also quantified in the three study groups. Both sIgE and sIgG were determined by means of the UniCAP 100 assay.
RESULTS: SPT and sIgE to GA were positive only in the 3 patients with adverse reactions while sIgE to mannitol was negative in all. sIgE tests against MBP and its fragments were negative in all individuals. Similar levels of sIgG to GA were found in all studied subjects.
CONCLUSION: These results demonstrate the significance of sIgE in allergic reactions to GA presented by these patients and suggest the importance of strict surveillance during administration of the first GA doses.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25634237     DOI: 10.1159/000371418

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  1 in total

Review 1.  Immediate reactions with glatiramer acetate: Diagnosis of allergy and desensitization protocols.

Authors:  Guadalupe Marco-Martín; Pilar Tornero; Alicia Prieto; Alejandro La Rotta; Teresa Herrero; Maria Luisa Baeza
Journal:  Neurol Clin Pract       Date:  2020-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.